What they told me is that even after a critical mass of the cancer cells evolved castrate resistance, there will still be many that are castrate-sensitive, and they will continue to respond to ADT and ARSI.

If I recall correctly, in the TITAN study, even subjects who did eventually evolve castrate resistance still had slower progression and longer overall survival while taking the ARSI.